Opaleye Management Inc. Viking Therapeutics, Inc. Transaction History

Opaleye Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $2.62 Million - $3.44 Million	-400,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $651,950 - $903,550	-85,000 Reduced 17.53%	400,000 $3.32 Million
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $2.58 Million - $3.38 Million	-340,000 Reduced 41.21%	485,000 $4.82 Million
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $3.64 Million - $7.37 Million	-375,000 Reduced 31.25%	825,000 $14.4 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $384,896 - $1.26 Million	99,200 Added 9.01%	1,200,000 $11.4 Million
Q1 2018 May 14, 2018	BUY	$4.11 - $6.93 $2.55 Million - $4.3 Million	620,242 Added 129.07%	1,100,800 $4.81 Million
Q4 2017 Feb 09, 2018	BUY	$1.74 - $4.34 $836,170 - $2.09 Million	480,558	480,558 $1.95 Million

460

65.4M

6.24M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.5B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.